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The humoral response to hepatitis C virus (HCV) may contribute to controlling infection. We
previously isolated human monoclonal antibodies to conformational epitopes on the HCV E2
glycoprotein. Here, we report on their ability to inhibit infection by retroviral pseudoparticles
incorporating a panel of full-length E1E2 clones representing the full spectrum of genotypes 1–6.
We identified one antibody, CBH-5, that was capable of neutralizing every genotype tested. It also
potently inhibited chimeric cell culture-infectious HCV, which had genotype 2b envelope
proteins in a genotype 2a (JFH-1) background. Analysis using a panel of alanine-substitution
mutants of HCV E2 revealed that the epitope of CBH-5 includes amino acid residues that are
required for binding of E2 to CD81, a cellular receptor essential for virus entry. This suggests that
CBH-5 inhibits HCV infection by competing directly with CD81 for a binding site on E2.
Hepatitis C virus (HCV) is a small, enveloped, positive-
strand RNA virus that infects an estimated 170 million
individuals worldwide (Anonymous, 1999). The virus
evades the immune system so successfully that most of
those who contract it remain chronically infected and may
eventually develop serious liver disease. HCV disables the
innate antiviral response by blocking pathways of inter-
feron induction and signalling (Gale & Foy, 2005; Meylan
& Tschopp, 2006) and escapes the adaptive immune
response largely by means of its genetic variability (Bowen
& Walker, 2005; Brown et al., 2005; Farci et al., 2000;
Shimizu et al., 1994; Thimme et al., 2006). There are six
distinct genotypes of HCV, each divided into subtypes
(Simmonds et al., 2005), and within a single individual the
virus exists as a constantly evolving quasispecies (Bukh
et al., 1995).
An effective T-cell response is essential for controlling HCV
infection (Bowen & Walker, 2005; Shoukry et al., 2004),
but neutralizing antibodies also play an important role. It
was observed long ago that immunoglobulin prophylaxis
protected against HCV infection (Conrad & Lemon, 1987;
Knodell et al., 1976) and it has recently been shown that
this protective effect correlates with the presence of
antibodies that can neutralize retroviral pseudoparticles
bearing HCV envelope glycoproteins (HCVpp) (Yu et al.,
2004). Studies of acutely infected cohorts show that rapid
induction of neutralizing antibodies may afford protection
(Lavillette et al., 2005a; Pestka et al., 2007). Moreover,
antibodies present during the acute phase of infection can
neutralize an infectious dose of HCV administered to
chimpanzees (Farci et al., 1994).
The envelope glycoproteins E1 and E2 are the natural
targets for neutralizing antibodies (Bartosch et al., 2003a;
Rosa et al., 1996). E2 binding to CD81 on the cell surface is
necessary, but not sufficient, for infection (Cocquerel et al.,
2006; Kapadia et al., 2007; Koutsoudakis et al., 2007). The
first hypervariable region (HVR-1) within the amino-
terminal part of E2 is involved in virus binding and entry
(Bartosch et al., 2003c) and is immunodominant.
Antibodies to HVR-1 neutralize infection, but they are
typically isolate-specific, with little or no recognition of
other isolates or genotypes. In contrast, conformational
epitopes on E2 outside HVR-1 are less prone to variation
and are able to elicit more broadly neutralizing antibodies
(Habersetzer et al., 1998; Hadlock et al., 2000; Johansson
et al., 2007; Perotti et al., 2008; Schofield et al., 2005).
We previously reported the generation of a panel of IgG1
human monoclonal antibodies (HmAbs) from the peri-
pheral B cells of an individual with asymptomatic HCV
genotype 1b infection (Hadlock et al., 2000). They
recognize conformational epitopes on E2 of more than
one genotype, and have been mapped to distinct domains, 3These authors contributed equally to this work.
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0008-3386 G 2008 SGM Printed in Great Britain 653designated A, B and C (Keck et al., 2004). The HmAbs that
recognize domains B and C block E2 binding to CD81 and
neutralize genotype 1a HCVpp and genotype 2a JFH-1 cell
culture-infectious HCV virions (HCVcc), whereas HmAbs
to domain A do not block CD81 binding and are non-
neutralizing (Hadlock et al., 2000; Keck et al., 2004, 2005,
2007; Op De Beeck et al., 2004).
Recent success in growing the genotype 2a JFH-1 isolate of
HCV in cultured cells to produce infectious virions
(Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al.,
2005) has yet to be replicated for all of the other genotypes.
However, various aspects of HCV binding and entry,
including antibody neutralization, can be studied by using
HCVpp (Bartosch et al., 2003b; Hsu et al., 2003). We have
assembled a panel of functional E1E2 glycoprotein
sequences representing all major genotypes (Lavillette
et al., 2005b; Owsianka et al., 2005; Tarr et al., 2006),
allowing us to extend the characterization of our previously
described HmAbs.
HCVpp displaying E1E2 of genotypes 1–6 and carrying a
luciferase reporter gene were generated in HEK293T cells
and purified as described previously (Bartosch et al., 2003b;
Owsianka et al., 2005). Aliquots of the HCVpp were mixed
with 100 mgm l
21 of each HmAb, incubated for 1 h at
37 uC and used to infect Huh-7 cells (Nakabayashi et al.,
1982). Luciferase activity in the infected cells was measured
after 4 days.
DomainB(CBH-2,-5,-8Cand-11)anddomainC(CBH-7)
HmAbs each had a distinct spectrum of neutralizing activity
against the genotype panel (Fig. 1a), whereas domain A
HmAbs did not reduce the infectivity of any genotype by
more than 25% (not shown). An isotype-matched control
HmAb against HCMV p64 (R04) did not reduce the
infectivity of any genotype by more than 10% (Fig. 1a).
CBH-5 reduced infectivity of HCVpp representing all
genotypes by at least 40%, whilst the other domain B
HmAbs each inhibited a more restricted range of
genotypes. CBH-2 neutralized HCVpp of genotypes 2a, 5
and 6 by at least 70%, and genotypes 2b and 4 by just
under 50%. It did not neutralize genotype 3a or genotype
1a clone H77c, although it neutralized the closely related
clone H by almost 50% (Fig. 1). These two clones differ at
five amino acid positions within E2, which may account for
the difference in CBH-2 neutralization. CBH-8C and CBH-
11 did not neutralize either of the 1a isolates, consistent
with previous findings that these HmAbs do not recognize
E2 of genotype 1a strain H (Keck et al., 2004). CBH-8C
neutralized genotypes 1b, 2a, 2b, 3a and 6, whilst CBH-11
showed modest neutralization of genotypes 1b, 2a, 2b and
6. The domain C HmAb CBH-7 neutralized both the 1a
strain H clones by more than 70%, genotypes 1b, 2a and
2b by about 40% and genotype 4 by 20%, but had no
effect on genotypes 3a, 5 or 6.
To examine the correlation between binding and neutral-
ization, we tested the binding of antibodies CBH-2, -5 and
-7 to E2 displayed on HCVpp. After sucrose-density
equilibrium centrifugation in 20–60% sucrose at
270000 g for 18 h at 4 uC, the infectious gradient fractions
were pooled, captured onto GNA (Galanthus nivalis
agglutinin)-coated plates and probed with each HmAb
over a range of concentrations. Bound antibodies were
detected with alkaline phosphatase-conjugated goat anti-
human IgG followed by p-nitrophenylphosphate disodium
hexahydrate, and A405 was measured.
CBH-5 was the most broadly reactive HmAb, giving a
robust, concentration-dependent signal with each genotype
(Fig. 1b). This broad reactivity clearly underpins its ability
to neutralize HCVpp across the spectrum of genotypes.
CBH-2 gave a concentration-dependent signal with E2 of
all genotypes except 1a H77c and 3a (Fig. 1b), which agrees
with its lack of ability to neutralize HCVpp bearing these
two sequences. Binding to genotype 4 was detectable only
at high CBH-2 concentrations. CBH-7 gave a strong
concentration-dependent signal with genotypes 1 and 2,
and a weaker one with genotypes 3–6, in agreement with its
neutralization profile. However, the relationship between
binding and neutralization was more complex for CBH-7,
as it recognized genotype 6 E2, but did not neutralize
genotype 6 HCVpp. It may be that greater saturation with
CBH-7 is required for neutralization or that there is a
difference in the mechanism of neutralization between
CBH-7 and the domain B antibodies.
We showed previously that CBH-5 and the other domain B
HmAbs potently neutralize genotype 2a (JFH-1) HCVcc,
whilst CBH-7 has modest HCVcc-neutralizing activity
(Keck et al., 2007). The half-maximal inhibitory concen-
tration (IC50) of these HmAbs is considerably lower for
HCVcc than for HCVpp (Keck et al., 2007). To see whether
this holds true for other isolates, we generated an
intragenotypic JFH-1 chimera carrying genotype 2b
(UKN2B1.1; Owsianka et al., 2005) E1E2 glycoproteins.
The 2b HCVcc were pre-incubated with HmAbs CBH-2, -5
and -7 over a range of concentrations before infecting
Huh-7 cells. After 4 days, the levels of viral RNA in these
cells were determined by real-time PCR (qRT-PCR) using
relative quantification, where each sample was normalized
to an endogenous control gene (glyceraldehyde-3-phos-
phate dehydrogenase).
All three HmAbs were very effective at reducing infectivity
(Fig. 2a), and the order of neutralization potency of these
antibodies for the 2b chimeric virus was the same as for the
genotype 2a virus: CBH-5.CBH-2.CBH-7. A similar
titration carried out with HCVpp displaying UKN2B1.1
E1E2 glycoproteins showed that all three HmAbs inhibited
infection at concentrations approximately two orders of
magnitude higher than those required for HCVcc neutral-
ization (Fig. 2b, c).
The difference between the IC50 (and IC90) values of all
three antibodies for HCVcc and HCVpp is striking. This
could be related to altered exposure or accessibility of
antibody epitopes, possibly resulting from differences in
A. M. Owsianka and others
654 Journal of General Virology 89Fig. 1. (a) Neutralization by HmAbs of HCVpp pseudotyped with E1E2 sequences of genotypes 1–6. This dataset is
representative of results obtained in at least three independent experiments. (b) Reactivity of HmAbs CBH-2 ($), CBH-5 (#)
and CBH-7 (.) with purified HCVpp in GNA ELISA. The following E1E2 sequences were used: genotype 1a, H77c (GenBank
accession no. AF011751) and H (Bartosch et al., 2003b; Helle et al., 2007); genotype 1b, UKN1B5.23 (AY734976); genotype
2a, UKN2A1.2 (AY734977); genotype 2b, UKN 2B1.1 (AY734982); genotype 3a, UKN3A13.6 (AY894683); genotype 4,
UKN4.11.1 (AY734986); genotype 5, UKN5.15.11 (AY894682); genotype 6, UKN6.5.8 (EF427671).
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HCVpp or the size difference between HCVpp and
authentic HCV virions (Sandrin et al., 2005). However,
the simplest explanation is that there is more non-
infectious E2 relative to infectious particles in a prepara-
tion of HCVpp than of HCVcc, and so more antibody is
required to neutralize HCVpp. Ideally, one would compare
the neutralization of equal numbers of particles or of equal
amounts of E2 presented on the two types of particles, but
it would be very hard to achieve this with any degree of
accuracy. The HCVpp system has been used in several
studies to determine virus neutralization by patient sera
(Farci et al., 1994; Lavillette et al., 2005a; Pestka et al., 2007;
Yu et al., 2004). Our results indicate that modest inhibition
of HCVpp may translate into more substantial neutraliza-
tion of infectious virus.
Domain B and C HmAbs all have neutralization-of-
binding (NOB) activity (Hadlock et al., 2000), so it is
likely that their epitopes overlap with regions of E2
involved in CD81 binding. Antibody blocking experiments
have implicated several regions of E2 in CD81 binding
(Clayton et al., 2002; Flint et al., 1999; Owsianka et al.,
2001). We identified conserved amino acid residues within
these regions and, using the 1a H77c sequence as a wild
type, made a panel of mutants in which each conserved
residue in turn was replaced by alanine. Some additional
mutants, available from other studies, were also included.
The mutations did not affect the overall conformation of
the E2 protein or its ability to form non-covalent
heterodimers with E1 (Owsianka et al., 2006). The mutant
proteins were expressed transiently in HEK 293T cells;
equivalent amounts of monomeric E2 protein were
captured on GNA plates and probed with antibodies
CBH-5 and CBH-7 at 2 mgm l
21. CBH-5 binding was
abrogated completely by mutations G523A, P525A, G530A,
D535A and N540A, indicating that these amino acid
residues may be involved in its recognition of E2 (Fig. 3).
Residues G523, P525, G530 and D535 are completely
conserved in functional sequences across all genotypes,
whereas N540 is not (Owsianka et al., 2006). G530 and
D535 are essential for CD81 interaction with E2, and G523
is also likely to be involved (Owsianka et al., 2006). The
residue corresponding to D535 in the JFH-1 virus is
essential for infectivity, as a point mutation at this position
renders HCVcc non-infectious (J. Witteveldt, unpublished
results). These data indicate that the epitope of CBH-5
includes four highly conserved amino acid residues, three
of which are involved in CD81 binding, suggesting that
CBH-5 exerts its potent neutralization of HCV infectivity
by competing directly with CD81 for binding to E2. This is
likely to account for its broad spectrum of activity, as any
changes in the CBH-5 epitope would be likely to affect
CD81 binding and virus entry.
N540 is important for recognition by both antibodies
because it is a glycosylation site, mutation of which
probably induces a local conformational change in E2,
which does not impair E2 folding and function severely,
but reduces the affinity of various neutralizing antibodies
including CBH-5 and CBH-7 (Goffard et al., 2005; Helle et
al., 2007). The only other mutation that reduced the
binding of CBH-7 substantially was W549A (Fig. 3). W549
is a highly conserved residue that is essential for HCVpp
infectivity, but not for CD81 binding (Owsianka et al.,
2006), which suggests that CBH-7 may act by steric
Fig. 2. Neutralization by HmAbs CBH-2 ($),
CBH-5 (#) and CBH-7 (.) of (a) genotype
2b HCVcc and (b) genotype 2b HCVpp. (c)
IC50 and IC90 of each HmAb for genotype 2b
HCVcc and HCVpp.
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Our panel of E2 proteins did not include mutants in all
regions of E2 that have been implicated in CD81 binding;
other studies have demonstrated the involvement of
residues 436–443 (Drummer et al., 2006) and 613–618
(Roccasecca et al., 2003). Further work is in progress to
define the epitopes of the domain B and C HmAbs more
completely, and how these relate to regions involved in
CD81 binding. It was not possible to use the same panel of
mutant E2 proteins to map the epitopes of CBH-2, -8C and
-11, as these bind poorly to the wild-type H77c sequence.
In this study of five conformation-sensitive anti-E2
HmAbs, tested for their ability to neutralize HCVpp
pseudotyped with glycoproteins of HCV genotypes 1–6,
only one antibody, CBH-5, was found to be active against
every E2 sequence. This highlights the need to use E1E2
from the full range of genotypes to identify truly broadly
neutralizing antibodies. Cross-reactive HmAbs specific for
conformational epitopes on E2 have been isolated and
characterized in several laboratories (Allander et al., 2000;
Bugli et al., 2001; Eren et al., 2006; Perotti et al., 2008;
Schofield et al., 2005), but such broad reactivity across all
genotypes has rarely been found (Johansson et al., 2007).
Broadly neutralizing antibodies are potentially of direct
clinical relevance. They could be used prophylactically to
reduce the risk of HCV infection after needlestick or other
accidental exposure. In the liver-transplant setting, it
would be very desirable to reduce the incidence of graft
reinfection by passive immunotherapy with antibodies
such as CBH-5. The characteristics of CBH-5 suggest that
there is at least one highly conserved neutralizing epitope
on the E2 glycoprotein to which the human immune
system is capable of mounting a response. This is
encouraging for future vaccine development, although
focusing the immune response on this epitope will
be challenging, given its conformational nature. Greater
knowledge of the structure of the HCV glycoproteins,
coupled with detailed mapping of the epitopes of
other neutralizing antibodies, should bring us closer to
this goal.
Fig. 3. Alanine-replacement mutagenesis.
Mutant proteins are annotated according to
the amino acid in the H77c sequence, the
amino acid position relative to the start of the
H77 polyprotein chain and the substitution
introduced. Binding of antibody to each mutant
protein is expressed as a percentage of
binding to wild-type H77c protein.
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